<p>CytoSorbents Corporation reported Q3 2025 revenue of $9.5 million, representing a 10% increase compared to $8.6 million in the same quarter last year, or 4% growth on a constant currency basis. The company attributed the performance to record sales in distributor territories and strong sales in other direct markets. Gross margin remained stable at approximately 70%. CytoSorbents continues to focus on achieving near-term cash flow breakeven, with expectations for cash flow breakeven beginning in Q1 2026. The company also reported $37 million in high margin product sales over the trailing twelve months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoSorbents Corporation published the original content used to generate this news brief on November 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

CTSO

<p>CytoSorbents Corporation reported Q3 2025 revenue of $9.5 million, a 10% increase from the previous year. The growth was driven by record sales in distributor territories and strong direct market sales. The gross margin remained stable at 70%. The company aims for cash flow breakeven by Q1 2026, with $37 million in high margin product sales over the past year.</p>

CytoSorbents Corporation reports Q3 2025 revenue of $9.5 million